

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



22 May 2026

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

**Additional Outcome of the Board Meeting held today, i.e., 22 May 2026**

---

Further to the earlier communication today i.e., [22 May 2026](#), this is to further inform that the Board of Directors of the Company, at its meeting held today, has, inter alia,

**1. Approved the requests for reclassification of certain promoter group individuals**

Further to our intimation dated [14 May 2026](#), the requests received for reclassification from the “Promoter Group” category to the “Public” category is approved, subject to receipt of necessary approvals as prescribed under the Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

**2. Approved and adopted the revised Code of Fair disclosure**

The revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (“Code”), has been approved and adopted by the Board and will be effective from 01 June 2026 and would be available on our website at [www.sunpharma.com](http://www.sunpharma.com).

The Board Meeting commenced at 10:45 AM, adjourned for a break, and was subsequently resumed and concluded at 4:00 PM.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983